풍선판막성형술 기기 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Balloon Valvuloplasty Devices Market Size, Share & Trends Analysis Report By Application (Aortic Valve Stenosis, Pulmonary Valve Stenosis), By End-use, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,407,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,820,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,646,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

풍선판막성형술 기기 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 풍선판막성형술 기기 시장 규모는 2025-2030년 연평균 4.1%의 연평균 복합 성장률(CAGR)을 보이고, 2030년까지 30억 2,000만 달러에 달할 것으로 예상됩니다.

심장판막증을 포함한 심혈관 질환의 유병률 증가, 신제품 출시, 규제 당국의 승인, 첨단 의료 인프라가 북미의 풍선 판막 성형기 수요를 견인하고 있습니다. 류마티스성 심장병(RHD)은 류마티스 열로 인한 심장 판막 손상으로 인해 발생하는 심각한 심혈관 질환입니다.

미국심장협회가 2024년 4월에 발표한 보고서에 따르면 심장판막증(VHD)은 미국에서 가장 널리 퍼져있는 건강 상태 중 하나로 성인 인구의 약 2.5%가 앓고 있는 것으로 나타났습니다. 대동맥판막질환과 승모판막질환은 VHD 중 가장 많이 진단되는 질환으로, 풍선판막성형술과 같은 효과적인 치료 옵션이 이 증가하는 건강 문제를 해결하는 데 필수적이라는 점을 더욱 강조하고 있습니다.

인식 개선과 검진 프로그램이 시장 성장을 가속하고 있습니다. 예를 들어 2024년 9월 세계 하트 허브는 2040년까지 2배, 2060년까지 3배로 증가할 것으로 예상되는 심장판막증 유병률 증가를 강조하는 캠페인을 시작했습니다. 이 캠페인은 정기적인 건강검진을 통한 조기 발견의 중요성을 강조하고 있습니다. 이 단체는 풍선판막성형술과 같은 증상과 가능한 치료법에 대해 대중에게 알리는 것을 목표로 하고 있습니다.

풍선판막성형술 기기 시장 : 분석 개요

• 용도별로는 대동맥판막 협착증 분야가 2024년 64.42% 이상의 최대 점유율을 차지했습니다. 전 세계 심장 판막 질환 발병률 증가와 기술 발전이 이 부문의 성장을 주도하고 있습니다.
• 최종 용도별로는 병원 부문이 2024년 57.4%로 최대의 매출 점유율을 차지했습니다. 전 세계에서 심장 판막 질환의 발병률이 증가함에 따라 병원내 환자 치료를 효과적으로 관리하기 위한 첨단 솔루션이 요구되고 있습니다.
• 북미는 심장판막증을 포함한 심혈관 질환 환자 수 증가로 인해 2024년 41.1%의 점유율을 차지했습니다. 제품 출시, 규제 당국의 승인, 첨단 의료 인프라가 풍선 판막 형성 장비에 대한 수요를 촉진하고 있습니다.

목차

제1장 분석 방법·범위

제2장 개요

제3장 풍선판막성형술 기기 시장 : 변동 요인·경향·범위

• 시장 연관 전망
  • 모시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 풍선판막성형술 기기 시장 : 분석 툴
  • 업계 분석 : Porter의 산업 분석
  • PESTEL 분석

제4장 풍선판막성형술 기기 시장 : 용도별 추정·동향 분석

• 풍선판막성형술 기기 시장 : 용도별 대시보드
• 풍선판막성형술 기기 시장 : 용도별 변동 분석
• 풍선판막성형술 기기 시장 : 시장 규모 예측과 동향 분석, 용도별(2018-2030년)
• 대동맥판 협착증
• 폐동맥판 협착증

제5장 풍선판막성형술 기기 시장 : 최종 용도별 추정·동향 분석

• 풍선판막성형술 기기 시장 : 최종 용도별 대시보드
• 풍선판막성형술 기기 시장 : 최종 용도별 변동 분석
• 풍선판막성형술 기기 시장 : 시장 규모 예측과 동향 분석, 최종 용도별(2018-2030년)
• 병원
• 외래 수술 센터(ASC)
• 심장 카테터 검사실

제6장 풍선판막성형술 기기 시장 : 지역별 추정과 동향 분석(용도별·최종 용도별)

• 세계의 풍선판막성형술 기기 시장 : 지역별 대시보드
• 시장 규모 예측과 동향 분석(2018-2030년)
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 스웨덴
  • 노르웨이
  • 덴마크
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 호주
  • 태국
  • 한국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 사우디아라비아
  • 남아프리카공화국
  • 아랍에미리트
  • 쿠웨이트

제7장 경쟁 구도

• 최근 동향과 영향 분석 : 주요 제조업체별
• 기업/경쟁의 분류
• 벤더 구도
  • 주요 판매 대리점 및 채널 파트너 리스트
  • Key customers
  • Key company market share analysis, 2024
  • B. Braun Interventional Systems, Inc.
  • BD
  • Edwards Lifesciences Corporation
  • Boston Scientific Corporation
  • Getinge
  • TORAY INTERNATIONAL AMERICA, INC.
  • Stryker
  • BrosMed Medical Co., Ltd.
  • Medtronic
  • Terumo Corporation
  • Koninklijke Philips NV

KSA

영문 목차

영문목차

Balloon Valvuloplasty Devices Market Growth & Trends:

The global balloon valvuloplasty devices market size is expected to reach USD 3.02 billion by 2030, registering a CAGR of 4.1% from 2025 to 2030, according to a new report by Grand View Research, Inc.The increasing prevalence of cardiovascular diseases, including valvular heart diseases, new product launches, regulatory approvals, and advanced healthcare infrastructure, drives the demand for balloon valvuloplasty devices in North America. Rheumatic heart disease (RHD) is a serious cardiovascular condition that arises from damage to the heart valves due to rheumatic fever.

According to a report published by the American Heart Association in April 2024, valvular heart disease (VHD) is among the most prevalent health conditions in the U.S., affecting about 2.5% of the adult population. Aortic and mitral valve diseases are the most diagnosed types of VHD, further emphasizing the critical need for effective treatment options like balloon valvuloplasty devices to address this growing health concern.

Increasing awareness and screening programs fuel the market's growth. For instance, in September 2024, the Global Heart Hub initiated campaigns highlighting the rising prevalence of heart valve disease, which is expected to double by 2040 and triple by 2060. These efforts stress the critical role of early detection through regular medical check-ups. The organization aims to inform the public about the symptoms and available treatments, such as balloon valvuloplasty.

Balloon Valvuloplasty Devices Market Report Highlights:

• Based on application, the aortic valve stenosis segment held the largest share, over 64.42%, in 2024. The global rise in the incidence of valvular heart diseases and technological advancements drive the segment's growth
• Based on end use, the hospital segment held the largest revenue share at 57.4% in 2024. The rising incidence of valvular heart diseases globally necessitates advanced solutions within hospitals to manage patient care effectively
• North America dominated the market with a share of 41.1% in 2024, owing to the rising cases of cardiovascular diseases, including valvular heart diseases. Product launches, regulatory approvals, and advanced healthcare infrastructure drive the demand for balloon valvuloplasty devices

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. End use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecast timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity price analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application Segment
  • 2.2.2. End use Segment
  • 2.2.3. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Global Balloon Valvuloplasty Devices Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of valvular heart diseases
    • 3.2.1.2. Technological advancements in balloon valvuloplasty devices
    • 3.2.1.3. Increasing awareness and screening programs
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost associated with the devices and procedures
    • 3.2.2.2. Regulatory compliance
• 3.3. Balloon Valvuloplasty Devices Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Balloon Valvuloplasty Devices Market: Application Estimates & Trend Analysis

• 4.1. Balloon Valvuloplasty Devices Market: Application Dashboard
• 4.2. Balloon Valvuloplasty Devices Market: Application Movement Analysis
• 4.3. Balloon Valvuloplasty Devices Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 4.4. Aortic Valve Stenosis
  • 4.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 4.5. Pulmonary Valve Stenosis
  • 4.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 5. Balloon Valvuloplasty Devices Market: End Use Estimates & Trend Analysis

• 5.1. Balloon Valvuloplasty Devices Market: End Use Dashboard
• 5.2. Balloon Valvuloplasty Devices Market: End Use Movement Analysis
• 5.3. Balloon Valvuloplasty Devices Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 5.4. Hospitals
  • 5.4.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 5.5. Ambulatory Surgical Centers (ASCs)
  • 5.5.1. Market estimates and forecasts 2018 to 2030, (USD Million)
• 5.6. Cardiac Catheterization Labs
  • 5.6.1. Market estimates and forecasts 2018 to 2030, (USD Million)

Chapter 6. Balloon Valvuloplasty Devices Market: Regional Estimates & Trend Analysis by Country, Application, & End use

• 6.1. Global Balloon Valvuloplasty Devices Market: Regional Dashboard
• 6.2. Market Size & Forecasts Trend Analysis, 2018 to 2030
• 6.3. North America
  • 6.3.1. Market Estimates and Forecasts 2018 to 2030, (USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.3.4. Mexico
    • 6.3.4.1. Key country dynamics
    • 6.3.4.2. Regulatory framework/ reimbursement structure
    • 6.3.4.3. Competitive scenario
    • 6.3.4.4. Mexico market estimates and forecast, 2018 - 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. Market Estimates and Forecasts 2018 to 2030, (USD Million)
  • 6.4.2. UK
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. UK market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.3. Germany
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.4. France
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. France market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.5. Italy
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.6. Spain
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.8. Norway
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4.9. Denmark
    • 6.4.9.1. Key country dynamics
    • 6.4.9.2. Regulatory framework/ reimbursement structure
    • 6.4.9.3. Competitive scenario
    • 6.4.9.4. Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Market Estimates and Forecasts 2018 to 2030, (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.3. Japan
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.4. India
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. India market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.5. Australia
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.5.7. South Korea
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Regulatory framework/ reimbursement structure
    • 6.5.7.3. Competitive scenario
    • 6.5.7.4. South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Market Estimates and Forecasts 2018 to 2030, (USD Million)
  • 6.6.2. Brazil
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. Market Estimates and Forecasts 2018 to 2030, (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7.3. South Africa
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7.4. UAE
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.7.5. Kuwait
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/ reimbursement structure
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Manufacturers
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company market share analysis, 2024
  • 7.3.4. B. Braun Interventional Systems, Inc.
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. BD
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Edwards Lifesciences Corporation
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Boston Scientific Corporation
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. Getinge
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. TORAY INTERNATIONAL AMERICA, INC.
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Stryker
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. BrosMed Medical Co., Ltd.
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Medtronic
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives
  • 7.3.13. Terumo Corporation
    • 7.3.13.1. Company overview
    • 7.3.13.2. Financial performance
    • 7.3.13.3. Product benchmarking
    • 7.3.13.4. Strategic initiatives
  • 7.3.14. Koninklijke Philips N.V.
    • 7.3.14.1. Company overview
    • 7.3.14.2. Financial performance
    • 7.3.14.3. Product benchmarking
    • 7.3.14.4. Strategic initiatives

관련자료